Adverse events associated with somatostatin analogs in acromegaly

Bibliography

• Melmed S. Acromegaly. N Engl J Med 2006;355:2558-73
   PubMed Web of Science ®Google Scholar
• Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004;25(1):102-52
   PubMed Web of Science ®Google Scholar
• Rosario PW, Calsolari MR. Screening for acromegaly by application of a single questionnaire evaluating the enlargement of extremities in adult patients seen at primary health care units. Pituitary 2012;15(2):179-83
   PubMed Web of Science ®Google Scholar
• Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006;91:4769-75
   PubMed Web of Science ®Google Scholar
• Ribeiro-Oliveira AJr, Barkan A. The changing face of acromegaly--advances in diagnosis and treatment. Nat Rev Endocrinol 2012;8(10):605-11
   PubMed Web of Science ®Google Scholar
• Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009;94(5):1509-17
   PubMed Web of Science ®Google Scholar
• Giustina A, Chanson P, Kleinberg D, et al. Expert consensus document: A consensus on the medical treatment of acromegaly. Nat Rev Endocrinol 2014;10(4):243-8
   PubMed Web of Science ®Google Scholar
• Giustina A, Chanson P, Bronstein MD, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010;95(7):3141-8
   PubMed Web of Science ®Google Scholar
• Anthony L, Freda PU. From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr Med Res Opin 2009;25(12):2989-99
   PubMed Web of Science ®Google Scholar
• Grasso LF, Pivonello R, Colao A. Somatostatin analogues as a first-line treatment in acromegaly: when is it appropriate? Curr Opin Endocrinol Diabetes Obes 2012;19(4):288-94
   PubMed Web of Science ®Google Scholar
• Auriemma RS, Pivonello R, Galdiero M, et al. Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: a retrospective, comparative, head-to-head study. J Endocrinol Invest 2008;31(11):956-65
   PubMed Web of Science ®Google Scholar
• Chanson P, Boerlin V, Ajzenberg C, et al. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf) 2000;53:577-86
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Auriemma RS, et al. Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months. J Clin Endocrinol Metab 2008;93(9):3436-42
   PubMed Web of Science ®Google Scholar
• Colao A, Lombardi G. Dose optimization of somatostatin analogues for acromegaly patients. J Endocrinol Invest 2010;33(2):125-7
   PubMed Web of Science ®Google Scholar
• Mercado M, Borges F, Bouterfa H, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 2007;66(6):859-68
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Lombardi G, Pivonello R. Resistance to somatostatin analogues in acromegaly. Endocr Rev 2011;32(2):247-71
   PubMed Web of Science ®Google Scholar
• Bogazzi F, Colao A, Rossi G, et al. Comparison of the effects of primary somatostatin analogue therapy and pituitary adenomectomy on survival in patients with acromegaly: a retrospective cohort study. Eur J Endocrinol 2013;169(3):367-76
   PubMed Web of Science ®Google Scholar
• Colao A, Vandeva S, Pivonello R, et al. Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy). Eur J Endocrinol 2014;171(2):263-73
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Auriemma RS, et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogues in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 2006;91(6):2112-18
   PubMed Web of Science ®Google Scholar
• Colao A, Ferone D, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001;86:2779-86
   PubMed Web of Science ®Google Scholar
• Petersenn S, Bollerslev J, Arafat AM, et al. Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: A randomized, multicenter, open-label, phase I study. J Clin Pharmacol 2014;54(11):1308-17
   PubMed Web of Science ®Google Scholar
• Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 2014;99(3):791-9
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controller acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2014. [Epub ahead of print]
   Google Scholar
• Krassas GE, Gogakos A, Boboridis K. Corticosteroids in the medical treatment of thyroid ophthalmopathy: when and how? Somatostatin analogues: where we stand today. Pediatr Endocrinol Rev 2010;7(Suppl 2):204-9
   PubMedGoogle Scholar
• Boehm BO. Use of long-acting somatostatin analogue treatment in diabetic retinopathy. Dev Ophthalmol 2007;39:111-21
   PubMedGoogle Scholar
• Hutchinson JM, Jennings JS, Jones RL. Long-acting somatostatin analogue therapy in obscure-overt gastrointestinal bleeding in noncirrhotic portal hypertension: a case report and literature review. Eur J Gastroenterol Hepatol 2010;22(6):754-8
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Floriani I, Bonadonna S, et al. Effects of somatostatin analogues on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 2009;94(5):1500-8
   PubMed Web of Science ®Google Scholar
• Freda PU. Somatostatin analogues in acromegaly. J Clin Endocrinol Metab 2002;87(7):3013-18
   PubMed Web of Science ®Google Scholar
• Jenkins PJ, Akker S, Chew SL, et al. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clin Endocrinol (Oxf) 2000;53(6):719-24
   PubMed Web of Science ®Google Scholar
• Auriemma RS, Pivonello R, Galdiero M, et al. Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: a retrospective, comparative, head-to-head study. J Endocrinol Invest 2008;31(11):956-65
   PubMed Web of Science ®Google Scholar
• Burt MG, Ho KK. Comparison of efficacy and tolerability of somatostatin analogues and other therapies for acromegaly. Endocrine 2003;20(3):299-305
   PubMed Web of Science ®Google Scholar
• Fleseriu M. Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Pituitary 2011;14(2):184-93
   PubMed Web of Science ®Google Scholar
• Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Arch Intern Med 1991;151(8):1573-8
   PubMed Web of Science ®Google Scholar
• Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients–a clinical research center study. J Clin Endocrinol Metab 1995;80(9):2768-75
   PubMed Web of Science ®Google Scholar
• Alexopoulou O, Abrams P, Verhelst J, et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 2004;151(3):317-24
   PubMed Web of Science ®Google Scholar
• Ambrosio MR, Franceschetti P, Bondanelli M, et al. Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in thetreatment of acromegaly. Metabolism 2002;51(3):387-93
   PubMed Web of Science ®Google Scholar
• Andries M, Glintborg D, Kvistborg A, et al. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin Endocrinol (Oxf) 2008;68(3):473-80
   PubMed Web of Science ®Google Scholar
• Attanasio R, Mainolfi A, Grimaldi F, et al. Somatostatin analogues and gallstones: a retrospective survey on a large series of acromegalic patients. J Endocrinol Invest 2008;31(8):704-10
   PubMed Web of Science ®Google Scholar
• Attanasio R, Baldelli R, Pivonello R, et al. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab 2003;88(11):5258-65
   PubMed Web of Science ®Google Scholar
• Ayuk J, Stewart SE, Stewart PM, Sheppard MC. Long-term safety and efficacy of depot long-acting somatostatin analogues for the treatment of acromegaly. J Clin Endocrinol Metab 2002;87(9):4142-6
   PubMed Web of Science ®Google Scholar
• Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002;87(1):99-104
   PubMed Web of Science ®Google Scholar
• Caron P, Bex M, Cullen DR, et al. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol (Oxf) 2004;60(6):734-40
   PubMed Web of Science ®Google Scholar
• Caron P, Cogne M, Raingeard I, et al. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf) 2006;64(2):209-14
   PubMed Web of Science ®Google Scholar
• Caron P, Morange-Ramos I, Cogne M, Jaquet P. Three year follow up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997;82(1):18-22
   PubMed Web of Science ®Google Scholar
• Chanson P, Borson-Chazot F, Kuhn JM, et al. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf) 2008;69(2):299-305
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Rebora A, et al. Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin Endocrinol (Oxf) 2009;71(2):237-47
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Auriemma RS, et al. Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 2007;157(5):579-87
   PubMed Web of Science ®Google Scholar
• Cozzi R, Dallabonzana D, Attanasio R, et al. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. Eur J Endocrinol 1999;141(3):267-71
   PubMed Web of Science ®Google Scholar
• Davies PH, Stewart SE, Lancranjan L, et al. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf) 1998;48(3):311-16
   PubMed Web of Science ®Google Scholar
• Giustina A, Bonadonna S, Bugari G, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol 2009;161(2):331-8
   PubMed Web of Science ®Google Scholar
• Jallad RS, Musolino NR, Salgado LR, Bronstein MD. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol (Oxf) 2005;63(2):168-75
   PubMed Web of Science ®Google Scholar
• Lin JD, Lee ST, Weng HF. An open, phase III study of lanreotide (Somatuline PR) in the treatment of acromegaly. Endocr J 1999;46(1):193-8
   PubMed Web of Science ®Google Scholar
• Lucas T, Astorga R; Spanish-Portuguese Multicentre Autogel Study Group on Acromegaly. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clin Endocrinol (Oxf) 2006;65(3):320-6
   PubMed Web of Science ®Google Scholar
• Maiza JC, Vezzosi D, Matta M, et al. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTRa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTRa. Clin Endocrinol (Oxf) 2007;67(2):282-9
   PubMed Web of Science ®Google Scholar
• Melmed S, Cook D, Schopohl J, et al. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary 2010;13(1):18-28
   PubMed Web of Science ®Google Scholar
• Caron P, Bevan J, Petersenn S, et al. Tumor shrinkage with lanreotide autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab 2014;99(4):1282-90
   PubMed Web of Science ®Google Scholar
• Ronchi CL, Boschetti M, Degli Uberti EC, et al. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol (Oxf) 2007;67(4):512-19
   PubMed Web of Science ®Google Scholar
• Salvatori R, Nachtigall LB, Cook DM, et al. Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly. Pituitary 2010;13(2):115-22
   PubMed Web of Science ®Google Scholar
• Shimatsu A, Teramoto A, Hizuka N, et al. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism. Endocr J 2013;60(5):651-63
   PubMed Web of Science ®Google Scholar
• Turner HE, Vadivale A, Keenan J, Wass JA. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin Endocrinol (Oxf) 1999;51(3):275-80
   PubMed Web of Science ®Google Scholar
• Tutuncu Y, Berker D, Isik S, et al. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly. Pituitary 2012;15(3):398-404
   PubMed Web of Science ®Google Scholar
• Verhelst JA, Pedroncelli AM, Abs R, et al. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol 2000;143(5):577-84
   PubMed Web of Science ®Google Scholar
• Catnach SM, Anderson JV, Fairclough PD, et al. Effect of octreotide on gall stone prevalence and gall bladder motility in acromegaly. Gut 1993;34(2):270-3
   PubMed Web of Science ®Google Scholar
• Erlinger S, Chanson P, Dumont M, et al. Effects of octreotide on biliary lipid composition and occurrence of cholesterol crystals in patients with acromegaly. A prospective study. Dig Dis Sci 1994;39(11):2384-8
   PubMed Web of Science ®Google Scholar
• Gullo L. Somatostatin analogues and exocrine pancreatic secretion. Digestion 1996;57(Suppl 1):93
   PubMedGoogle Scholar
• Williams ST, Woltering EA, O’Dorisio TM, Fletcher WS. Effect of octreotide acetate on pancreatic exocrine function. Am J Surg 1989;157(5):459-62
   PubMed Web of Science ®Google Scholar
• Konturek SJ, Bilski J, Jaworek J, et al. Comparison of somatostatin and its highly potent hexa- and octapeptide analogues on exocrine and endocrine pancreatic secretion. Proc Soc Exp Biol Med 1988;187(2):241-9
   PubMed Web of Science ®Google Scholar
• Schlegel W, Raptis S, Harvey RF, et al. Inhibition of cholecystokinin-pancreozymin release by somatostatin. Lancet 1977;2(8030):166-8
   PubMed Web of Science ®Google Scholar
• Ho PJ, Boyajy LD, Greenstein E, et al. Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly. Dig Dis Sci 1993;38(2):309-15
   PubMed Web of Science ®Google Scholar
• Redfern JS, Fortuner WJII. Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management. Am J Gastroenterol 1995;90(7):1042-52
   PubMed Web of Science ®Google Scholar
• Avila NA, Shawker TH, Roach P, et al. Sonography of gallbladder abnormalities in acromegaly patients following octreotide and ursodiol therapy: incidence and time course. J Clin Ultrasound 1998;26(6):289-94
   PubMed Web of Science ®Google Scholar
• Paisley AN, Roberts ME, Trainer PJ. Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems. Clin Endocrinol (Oxf) 2007;66(5):723-6
   PubMed Web of Science ®Google Scholar
• Moschetta A, Stolk MF, Rehfeld JF, et al. Severe impairment of postprandial cholecystokinin release and gall-bladder emptying and high risk of gallstone formation in acromegalic patients during Sandostatin LAR. Aliment Pharmacol Ther 2001;15(2):181-5
   PubMed Web of Science ®Google Scholar
• Hussaini SH, Pereira SP, Veysey MJ, et al. Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones. Gut 1996;38(5):775-83
   PubMed Web of Science ®Google Scholar
• Hofmann AF. Increased deoxycholic acid absorption and gall stones in acromegalic patients treated with octreotide: more evidence for a connection between slow transit constipation and gall stones. Gut 2005;54(5):575-8
   PubMed Web of Science ®Google Scholar
• Montini M, Gianola D, Pagani MD, et al. Cholelithiasis and acromegaly: therapeutic strategies. Clin Endocrinol (Oxf) 1994;40(3):401-6
   PubMed Web of Science ®Google Scholar
• Thomas LA, Veysey MJ, Murphy GM, et al. Octreotide induced prolongation of colonic transit increases faecal anaerobic bacteria, bile acid metabolising enzymes, and serum deoxycholic acid in patients with acromegaly. Gut 2005;54(5):630-5
   PubMed Web of Science ®Google Scholar
• Internal Clinical Guidelines Team (UK). Gallstone disease: diagnosis and management of cholelithiasis, cholecystitis and choledocholithiasis. National Institute for Health and Care Excellence (UK), London; 2014
   Google Scholar
• Giordano C, Ciresi A, Amato MC, et al. Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. Pituitary 2012;15(4):539-51
   PubMed Web of Science ®Google Scholar
• Ronchi CL, Varca V, Beck-Peccoz P, et al. Comparison between six-year therapy with long-acting somatostatin analogues and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 2006;91(1):121-8
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Savastano S, et al. Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study. J Clin Endocrinol Metab 2009;94(8):2907-14
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Galdiero M, et al. Impact of somatostatin analogues versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. J Clin Endocrinol Metab 2009;94(2):528-37
   PubMed Web of Science ®Google Scholar
• Annamalai AK, Webb A, Kandasamy N, et al. A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J Clin Endocrinol Metab 2013;98(3):1040-50
   PubMed Web of Science ®Google Scholar
• Couture E, Bongard V, Maiza JC, et al. Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotide. Pituitary 2012;15(4):518-25
   PubMed Web of Science ®Google Scholar
• Baldelli R, Battista C, Leonetti F, et al. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol (Oxf) 2003;59(4):492-9
   PubMed Web of Science ®Google Scholar
• Kreze A, Kreze-Spirova E, Mikulecky M. Risk factors for glucose intolerance in active acromegaly. Braz J Med Biol Res 2001;34:1429-33
   PubMed Web of Science ®Google Scholar
• Ciresi A, Amato MC, Pivonello R, et al. The metabolic profile in active acromegaly is gender-specific. J Clin Endocrinol Metab 2013;98(1):E51-9
   PubMed Web of Science ®Google Scholar
• Kasayama S, Otsuki M, Takagi M, et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 2000;52:549-55
   PubMed Web of Science ®Google Scholar
• Ho KK, Jenkins AB, Furler SM, et al. Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin Endocrinol (Oxf) 1992;36(3):271-9
   PubMed Web of Science ®Google Scholar
• Colao A. Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. Pituitary 2012;15(1):50-8
   PubMed Web of Science ®Google Scholar
• Singh V, Brendel MD, Zacharias S, et al. Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab 2007;92(2):673-80
   PubMed Web of Science ®Google Scholar
• Braun M. The somatostatin receptor in human pancreatic β-cells. Vitam Horm 2014;95:165-93
   PubMed Web of Science ®Google Scholar
• Lamberts SW, Uitterlinden P, Verschoor L, et al. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 1985;313(25):1576-80
   PubMed Web of Science ®Google Scholar
• Breidert M, Pinzer T, Wildbrett J, et al. Long-term effect of octreotide in acromegaly on insulin resistance. Horm Metab Res 1995;27(5):226-30
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Galdiero M, et al. Effects of initial therapy for five years with somatostatin analogues for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab 2009;94(10):3746-56
   PubMed Web of Science ®Google Scholar
• Steffin B, Gutt B, Bidlingmaier M, et al. Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur J Endocrinol 2006;155(1):73-8
   PubMed Web of Science ®Google Scholar
• Gutt B, Bidlingmaier M, Kretschmar K, et al. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel). Exp Clin Endocrinol Diabetes 2005;113(3):139-44
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Porcelli T, Bogazzi F, et al. Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. Eur J Endocrinol 2011;164(3):341-7
   PubMed Web of Science ®Google Scholar
• Ashwell SG, Bevan JS, Edwards OM, et al. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol 2004;150(4):473-80
   PubMed Web of Science ®Google Scholar
• Herrington AM, George KW, Moulds CC. Octreotide-induced bradycardia. Pharmacotherapy 1998;18(2):413-16
   PubMed Web of Science ®Google Scholar
• Fatti LM, Scacchi M, Lavezzi E, et al. Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients. Clin Endocrinol (Oxf) 2006;65(5):626-30
   PubMed Web of Science ®Google Scholar
• Nakauchi Y, Kumon Y, Yamasaki H, et al. Scalp hair loss caused by octreotide in a patient with acromegaly: a case report. Endocr J 1995;42(3):385-9
   PubMed Web of Science ®Google Scholar
• Christensen SE, Weeke J, Kaal A, et al. SMS 201-995 and thyroid function in acromegaly: acute, intermediate and long-term effects. Horm Metab Res 1992;24(5):237-9
   PubMed Web of Science ®Google Scholar
• Itoh S, Tanaka K, Kumagae M, et al. Effect of subcutaneous injection of a long-acting analogue of somatostatin (SMS 201-995) on plasma thyroid-stimulating hormone in normal human subjects. Life Sci 1988;42(26):2691-9
   PubMed Web of Science ®Google Scholar
• Grasso LF, Pivonello R, Colao A. Investigational therapies for acromegaly. Expert Opin Investig Drugs 2013;22(8):955-63
   PubMed Web of Science ®Google Scholar
• Henry RR, Ciaraldi TP, Armstrong D, et al. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 2013;98(8):3446-53
   PubMed Web of Science ®Google Scholar
• Zambre Y, Ling Z, Chen MC, et al. Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogues directed to somatostatin receptor subtype 5. Biochem Pharmacol 1999;57:1159-64
   PubMed Web of Science ®Google Scholar
• Colao A, De Block C, Gaztambide MS, et al. Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations. Pituitary 2014;17(2):180-6
   PubMed Web of Science ®Google Scholar
• Breitschaft A, Hu K, Hermosillo Reséndiz K, et al. Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract 2014;103(3):458-65
   PubMed Web of Science ®Google Scholar
• Tuvia S, Atsmon J, Teichman SL, et al. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab 2012;97(7):2362-9
   PubMed Web of Science ®Google Scholar
• Melmed S, Popovic V, Bidlingmaier M, et al. Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial. J Clin Endocrinol Metab 2015;100(4):1699-708
   PubMed Web of Science ®Google Scholar